We are live on ! Find out more
CTOR

Citius Oncology

7 hedge funds and large institutions have $990K invested in Citius Oncology in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

913% more capital invested

Capital invested by funds: $97.7K → $990K (+$892K)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

0.17% more ownership

Funds ownership: 0.15% → 0.32% (+0.17%)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CTOR Hedge Fund Activity: Q2 2025 in Review

7 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q2 2025, worth a combined $990K — up 913% from $97.7K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CTOR positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $125K. The largest seller was UBS Group, cutting an estimated $40.1K.

  • 7 institutional investors held Citius Oncology (CTOR) as of Q2 2025, up from 6 in Q1 2025.
  • Funds reported $990K of Citius Oncology stock for Q2 2025, up 913% quarter-over-quarter.
  • 2 funds opened new Citius Oncology positions in Q2 2025 and 1 closed out, a net change of +1 holder.
  • The largest Citius Oncology buyer in Q2 2025 was Jane Street, an estimated $125K added.
  • The largest Citius Oncology seller in Q2 2025 was UBS Group, an estimated $40.1K sold.

Based on aggregated 13F filings for Q2 2025.